Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What an itty, bitty, tiny little market cap we have here for a company about to be enrolling in multiple p2 Covid-19 drug trials.
Expecting to see this change in the month of May
Good morning everyone looking forward to a green day here
Coronavirus aint going away, unfortunately, they will be able to enroll folks.
During an interview with biopub on 4/13 they stated that they anticipated filing an IND with the US FDA within 1-2 weeks.
Now, timelines like this in biotech are always rosy. I've invested in dozens of biotech stocks for decades and 99% of them miss their deadlines.....but the good ones do eventually get there.
I think it's realistic to double that timeframe and in the next 1-2 weeks we will see and IND filed with the US FDA which is HUGE.
Yes sir although we already have South Korean approval. Enrollment begins May 8th. Data should be 2-4 weeks behind.
NO I will not be daydrinking again.
Although last time we did that it ramped to 20% to .39.........
Today is one of those pound the table moments that I'll be proud to look back on. SHOULD'VE BOUGHT!
Watch out when the FDA IND hits the newswire and the South Korean trial begins enrollment in a few weeks.
This is not a pump and dump folks this company has a legit drug that, if effective, will ramp the value of this 10x, 20x, 30x, or more.
Days like this are the days to buy, boring. But things can move and will move quickly here.
I think there is a good chance they file a formal IND with the FDA this week and if/when that happens I think we see a catapult in price.
Trade around a core if you get bored but this is going to ramp here SOON
Probably not today but it's going much higher later this week
It's early they are beginning 4 covid-19 clinical trials with a safe drug that has a terrific rationale that it may work. Independent Chinese investigators showed it works in influenza.
The window until lift off is short and we'll see some BS, until we don't :)
Yes but the overall trend is up.
Some stocks I trade around a core, keep around 80% but try and flip 20% of the position by selling after strong runs and buying back on dips like today.
Canada and USA acceptance, along with South Korean enrollment/data will be the real drivers behind this and that should happen middle of May. It's games until then.
We may have to deal with these games for a week or two. It was almost .40 middle of last week, can easily get back up there this week.
Big moves incoming. Buy all dips.
I did just smack the ask for 15k shares....and it didnt move. Well, my work here today seems done.
Looking forward for biopub interview Thursday. They give good info last one was two hours. Be back then!
Lotta volume early on
Looks like another BioPub webcast this Thursday at noon. Eager to hear more from the duo
Maybe I'll write him a letter. Worked for the last guy
Well I am still glad we got the South Korean trial approval but I won't be day drinking again now matter how good the news we get is.
That was rough....
Story time:
We surged up Monday 20% from the mid .20s to the upper .20s and a bunch of traders made $100 bucks. Good work! But some held.
These traders probably made some other trades Tuesday and Wednesday and almost certainly lost their $100. Because they are dumb traders.
Meanwhile those that held here and INVESTED IN SCIENCE are up another 20%+ from Monday, 40% on the week.
Watch closely friends. $AGNPF
I know a lot of strong money who bought in today for the ride up. For the rest who did lets pat yourselves on the back.
Let the traders trade for pennies.
Be early, be right, hold tight.
Obviously a lot of traders here. Glad they made $100 today they will soon be left behind.
Wait till FDA Submission and acceptance. Talk about validation.
It's almost sure to provide a clinical benefit. Mega money to be made here.
Looks like a few traders are exiting for their $100-$200 gains meanwhile I am sitting here drinking some beer and up almost 5 grand on the week.
Easier to sit on a winner than to trade it, trust me. Watch closely friends.
For perspective - Gilead gained *BILLIONS* in market cap - 14% in AH last week - after a report that Remdesivir showed clinical benefit in a Chicago hospital.
Clinical benefit shown here will catapult this megafold. Watching closely. I think it's very possible. $AGNPF
If we ramp back to high of day I am selling others and doubling my position again. That will signal conviction. Pays to be in early.
The MC here is laughable for a company that can be a player in the covid-19 treatment universe.
Ive seen a lot of penny stocks where people focus in on flipping for pennies while missing out on massive gains - TRIL being the most recent.
This ain't one to flip the science is there my friends.
I did the same in the low 30s, was an easy decision. This can be multiples higher in the coming weeks and months. Fastest Ive bought into a position I think ever.
It's very under most people's radar for now but it won't be for long. Things are moving along quickly and its paltry MC is sure to explode many-fold here soon.
Can somebody please correct me if I am wrong but I thought during the BIOPUB interview they said in approximately 2 weeks they would be submitting their application for clinical trials to the FDA.
So that would be next week as that interview was on 4/13. Is this correct? $AGNPF
Agreed we should have hard data sometime in June. Very exciting.
Only a matter of time before this becomes recognized for its potential. Trading at a fraction of the costs of what it will be worth in 2-5 months time. Enjoying every moment of it........
Early innings of the game here folks. June will be where the big money is won.
I believe we see the big pop once they submit an application to the US FDA. FDA news always moves these more..
That's not saying today's news is insignificant. I like that we now have a timeline on trials and pending data. And the timeline is short, we'll know if this works in humans very shortly.
If it does.........Boom goes the dynamite.
Yup any speculation will be over soon. We'll know alot by the end of June.
BREAKING NEWS Covid-19 $AGNPF Phase 2 trial approval
Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea
pril 23, 2020 07:30 ET | Source: Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 23, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has received approval from the Ministry of Food and Drug Safety in South Korea, as well as ethics approval, for an investigator-led, Phase 2 COVID-19 clinical study of its re-purposed drug NP-120 (Ifenprodil), an NMDA receptor antagonist.
The Lead Principal Investigator is Dr. Dong Sik Jung, Professor, in the Division of Infectious Disease of Dong-A University Hospital, Busan.
The 40-patient, 4-week trial, is designed to test the effect of Ifenprodil in COVID-19 infected patients with severe pneumonia. Patients are randomized in a 1:1 fashion to receive either standard of care (SOC) or SOC with Ifenprodil. The primary endpoint will be the rate at which their lung function improves by measuring oxygen levels in the blood (Pa02/Fi02). Secondary endpoints will include mortality, rate of mechanical ventilation, and patient reported effects on cough and breathlessness (dyspnea).
Enrollment in the phase 2 clinical trial is expected to begin on May 8, 2020.
“This first human trial of Ifenprodil in COVID-19 patients is a major step forward with our new acute lung injury clinical research program,” said Christopher J. Moreau CEO of Algernon. “Positive Phase 2 data would be an important milestone as we continue to investigate Ifenprodil’s therapeutic potential as a treatment for COVID-19, in addition to advancing our idiopathic pulmonary fibrosis and chronic cough program.”
The Company cautions that while it is preparing to begin a Phase 2 clinical trial shortly in South Korea, it is not making any express or implied claims that NP-120 (Ifenprodil) is an effective treatment for acute lung injury (ALI), the COVID-19 virus, or any other medical condition at this time.
Data coming in June expect much higher prices by then.
BREAKING NEWS Covid-19 $AGNPF Phase 2 trial approval
Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea
pril 23, 2020 07:30 ET | Source: Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 23, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has received approval from the Ministry of Food and Drug Safety in South Korea, as well as ethics approval, for an investigator-led, Phase 2 COVID-19 clinical study of its re-purposed drug NP-120 (Ifenprodil), an NMDA receptor antagonist.
The Lead Principal Investigator is Dr. Dong Sik Jung, Professor, in the Division of Infectious Disease of Dong-A University Hospital, Busan.
The 40-patient, 4-week trial, is designed to test the effect of Ifenprodil in COVID-19 infected patients with severe pneumonia. Patients are randomized in a 1:1 fashion to receive either standard of care (SOC) or SOC with Ifenprodil. The primary endpoint will be the rate at which their lung function improves by measuring oxygen levels in the blood (Pa02/Fi02). Secondary endpoints will include mortality, rate of mechanical ventilation, and patient reported effects on cough and breathlessness (dyspnea).
Enrollment in the phase 2 clinical trial is expected to begin on May 8, 2020.
“This first human trial of Ifenprodil in COVID-19 patients is a major step forward with our new acute lung injury clinical research program,” said Christopher J. Moreau CEO of Algernon. “Positive Phase 2 data would be an important milestone as we continue to investigate Ifenprodil’s therapeutic potential as a treatment for COVID-19, in addition to advancing our idiopathic pulmonary fibrosis and chronic cough program.”
The Company cautions that while it is preparing to begin a Phase 2 clinical trial shortly in South Korea, it is not making any express or implied claims that NP-120 (Ifenprodil) is an effective treatment for acute lung injury (ALI), the COVID-19 virus, or any other medical condition at this time.
Data coming in June expect much higher prices by then.
Enrollment in the phase 2 clinical trial is expected to begin on May 8, 2020.
The 40-patient, 4-week trial, is designed to test the effect of Ifenprodil in COVID-19 infected patients with severe pneumonia. Patients are randomized in a 1:1 fashion to receive either standard of care (SOC) or SOC with Ifenprodil.
We should have some data in June. 10 bagger central....
GLTA Longs!
Literally less than 1 minute after I posted this i saw the news. World works in mysterious ways sometimes...
Let's do it ??
Good morning everyone. Hope we hear about South Korean trial approval soon. I will start day drinking the morning of that news